Literature DB >> 12673715

Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis.

Maurice P A Zeegers1, Annemarie Jellema, Harry Ostrer.   

Abstract

BACKGROUND: Although narrative reviews have concluded that there is strong support for familial clustering of prostate carcinoma, the association has never systematically been quantified in reviews. The purpose of this meta-analysis was to summarize and quantify the recurrence risk ratio with emphasis on the degree of relation, the specific relationship of the family member, the number of affected family members, and the age at diagnosis.
METHODS: Publications were identified through computerized database searches for epidemiologic studies published up to December 2002. In addition, references cited in original and review papers were examined. Three blinded reviewers extracted both qualitative and quantitative information from each paper. Using random effects meta-regression analyses, the authors calculated summary recurrence risk ratios (S(lambda)). The reviewers also evaluated changes in S(lambda) according to differences in study methodology.
RESULTS: Thirty-three epidemiologic studies were included in the current review. S(lambda) was 2.53 (95% confidence interval, 2.24-2.85) for first-degree family members. S(lambda) appeared to be greater for men with an affected brother than for men with an affected father. S(lambda) for men who had second-degree relatives with prostate carcinoma was only slightly elevated. The nature of the familial clustering is such that S(lambda) increases with decreasing age of the patient and family members, with increasing genetic relatedness of the affected relative, and with increasing number of individuals affected within a family.
CONCLUSIONS: The studies that were reviewed consistently demonstrate that family history is a significant risk factor for development of prostate carcinoma. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Year:  2003        PMID: 12673715     DOI: 10.1002/cncr.11262

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  53 in total

1.  Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer.

Authors:  Ethan M Lange; Jessica V Ribado; Kimberly A Zuhlke; Anna M Johnson; Gregory R Keele; Jin Li; Yunfei Wang; Qing Duan; Ge Li; Zhengrong Gao; Yun Li; Jianfeng Xu; S Lilly Zheng; Kathleen A Cooney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-15       Impact factor: 4.254

2.  C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.

Authors:  Brandon L Pierce; Mary L Biggs; Marvalyn DeCambre; Alexander P Reiner; Christopher Li; Annette Fitzpatrick; Christopher S Carlson; Janet L Stanford; Melissa A Austin
Journal:  Cancer Causes Control       Date:  2009-03-08       Impact factor: 2.506

3.  [Risks and prevention of prostate cancer. Commentary on the new S3 guideline].

Authors:  B J Schmitz-Dräger; E Bismarck; G Lümmen
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

Review 4.  African-American Prostate Cancer Disparities.

Authors:  Zachary L Smith; Scott E Eggener; Adam B Murphy
Journal:  Curr Urol Rep       Date:  2017-08-14       Impact factor: 3.092

5.  The influence of occupational exposure to pesticides, polycyclic aromatic hydrocarbons, diesel exhaust, metal dust, metal fumes, and mineral oil on prostate cancer: a prospective cohort study.

Authors:  D Boers; M P A Zeegers; G M Swaen; Ij Kant; P A van den Brandt
Journal:  Occup Environ Med       Date:  2005-08       Impact factor: 4.402

Review 6.  Prostate cancer in young men: an important clinical entity.

Authors:  Claudia A Salinas; Alex Tsodikov; Miriam Ishak-Howard; Kathleen A Cooney
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

7.  Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.

Authors:  Ilir Agalliu; Robert Gern; Suzanne Leanza; Robert D Burk
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  Quality of systematic reviews of observational nontherapeutic studies.

Authors:  Tatyana Shamliyan; Robert L Kane; Stacy Jansen
Journal:  Prev Chronic Dis       Date:  2010-10-15       Impact factor: 2.830

9.  Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer.

Authors:  Shaheen Alanee; Sohela Shah; Joseph Vijai; Kasmintan Schrader; Robert Hamilton; Rohini Rau-Murthy; Kara Sarrel; Christopher Manschreck; James Eastham; Kenneth Offit
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

10.  Cancer risk assessment for the primary care physician.

Authors:  Larissa A Korde; Shahinaz M Gadalla
Journal:  Prim Care       Date:  2009-09       Impact factor: 2.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.